Pharmaceutical entrepreneur and philanthropist Kumar Muthalagappan OBE has started a new advisory role with US-based oncology research organization START. Muthalagappan will assist the Phase 1 oncology research organization South Texas Accelerated Research Therapeutics (START) in its quest to expand globally – particularly into Europe and other markets.
With 10 existing sites globally – principally in America as well as Dublin, Barcelona, Rioja, Madrid and Lisbon – START’s key aim is to accelerate the development of anti-cancer drugs, helping to improve the quality of life and survival rates for patients with cancer and to lead to its eventual cure.
Muthalagappan's new role follows another new appointment earlier this year as Strategic Advisor and Catalyst Council Member of CRIO – an e-Source solution which collects patient data for the purpose of clinical research trials.
Muthalagappan brings a wealth of experience to his new roles. In 2009 he was called upon to give strategic advice to MeDiNova – a small clinical research company undertaking clinical trials for a range of conditions such as asthma, COPD and osteoporosis with the principal aim of bringing novel treatments to patients. He later took the helm as company CEO and Chairman, growing turnover from £500,000 to £40 million and growing MeDiNova to 106 sites in eight different countries, resulting in providing treatment opportunities to thousands of patients in varying communities. He later established global cancer clinical research company Oncacare – bringing patients, oncologists and pharmaceutical organizations together and driving global oncology developments, aiding the successful treatment of cancer and bringing fresh hope to millions of cancer patients worldwide.
“I am delighted to be given the opportunity to bring my experience and expertise to START as it seeks to extend its reach into more countries, benefiting thousands more people across the world," said Muthalagappan.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
